ﺍﺭﺗﺒﺎﻁ ﺍﺳﺘﻮﻣﺎﺗﻴﺖ ﺁﻓﺘﻲ ﺭﺍﺟﻌﻪ ﺑﺎ ﮐﻤﺒﻮﺩ ﻭﻳﺘﺎﻣﻴﻦ ﺏ 12 ﻭ ﺍﺳﻴﺪﻓﻮﻟﻴﮏ

VITAMIN B12 an‎d FOLIC ACID DEFICIENCY IN PATIENTS WITH RECURRENT APHTHOUS STOMATITIS: A CROSS-SECTIONAL STUDY

ﺗﺎرﯾﺦ درﯾﺎﻓﺖ 1399/05/24 ﺗﺎرﯾﺦ ﭘﺬﯾﺮش 1399/10/05 ﭼﮑﻴﺪﻩ ﭘﻴﺶﺯﻣﻴﻨﻪ ﻭ ﻫﺪﻑ: ﺁﻓﺖ ﺭﺍﺟﻌﻪﻱ ﺩﻫﺎﻧﻲ ﻳﮑﻲ ﺍﺯ ﺷﺎﻳﻊﺗﺮﻳﻦ ﺑﻴﻤﺎﺭﻱﻫﺎﻱ ﺩﺍﺧﻞ ﺩﻫﺎﻧﻲ ﺍﺳﺖ. ﻋﻠﺖ ﺑﺮﻭﺯ ﺑﻴﻤﺎﺭﻱ ﺑﻪﻃﻮﺭ ﺩﻗﻴﻖ ﻣﺸﺨﺺ ﻧﻴﺴﺖ. ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﻧﻘﺶ ﮐﻤﺒﻮﺩ ﻭﻳﺘﺎﻣﻴﻦ B12 ﻭ ﺍﺳﻴﺪﻓﻮﻟﻴﮏ ﺩﺭ ﺑﺮﻭﺯ ﻧﺎﻫﻨﺠﺎﺭﻱﻫﺎﻱ ﺍﻟﺘﻬﺎﺑﻲ ﻣﺨﺎﻃﻲ، ﺩﺭ ﺍﻳﻦ ﻣﻄﺎﻟﻌﻪ ﺑﻪ ﺍﺭﺯﻳﺎﺑﻲ ﻧﻘﺶ ﮐﻤﺒﻮﺩ ﻭﻳﺘﺎﻣﻴﻦ B12 ﻭ ﺍﺳﻴﺪﻓﻮﻟﻴﮏ ﺩﺭ ﺑﺮﻭﺯ ﺍﺳﺘﻮﻣﺎﺗﻴﺖ ﺁﻓﺘﻲ ﺭﺍﺟﻌﻪ ﭘﺮﺩﺍﺧﺘﻴﻢ. ﻣﻮﺍﺩ ﻭ ﺭﻭﺵﻫﺎ: ﺩﺭ ﺍﻳﻦ ﻣﻄﺎﻟﻌﻪ ﺑﻴﻤﺎﺭﺍﻥ ﻣﺮﺍﺟﻌﻪﮐﻨﻨﺪﻩ ﺑﻪ ﺑﻴﻤﺎﺭﺳﺘﺎﻥ ﺁﻳﺖ ﺍ... ﻃﺎﻟﻘﺎﻧﻲ ﺷﻬﺮ ﺍﺭﻭﻣﻴﻪ ﻭﺍﺭﺩ ﻣﻄﺎﻟﻌﻪ ﺷﺪﻧﺪ. ﺑﻴﻤﺎﺭﺍﻥ ﺩﺍﺭﺍﻱ ﺑﻴﻤﺎﺭﻱﻫﺎﻱ ﺯﻣﻴﻨﻪﺍﻱ ﻭ ﺑﺎﻻﻱ 50 ﺳﺎﻝ ﺍﺯ ﻣﻄﺎﻟﻌﻪ ﺣﺬﻑ ﺷﺪﻧﺪ. ﺑﻴﻤﺎﺭﺍﻥ ﺍﺯﻧﻈﺮ ﻭﺟﻮﺩ ﻋﻼﺋﻢ ﺁﺳﺘﻮﻣﺎﺗﻴﺖ ﺁﻓﺘﻲ ﺭﺍﺟﻌﻪ ﺍﺭﺯﻳﺎﺑﻲ ﺷﺪﻧﺪ. ﺑﻴﻤﺎﺭﺍﻥ ﺑﺮ ﺍﺳﺎﺱ ﺍﺑﺘﻼ ﺑﻪ ﺍﺳﺘﻮﻣﺎﺗﻴﺖ ﺁﻓﺘﻲ ﺭﺍﺟﻌﻪ ﺑﻪﺻﻮﺭﺕ ﺗﺼﺎﺩﻓﻲ ﺩﻭ ﮔﺮﻭﻩ ﺩﺍﺭﺍﻱ ﺿﺎﻳﻌﻪ )ﻣﻄﺎﻟﻌﻪ( ﻭ ﺑﺪﻭﻥ ﺿﺎﻳﻌﻪ )ﮐﻨﺘﺮﻝ( ﺗﻘﺴﻴﻢﺑﻨﺪﻱ ﺷﺪﻧﺪ. ﺳﻄﺢ ﻭﻳﺘﺎﻣﻴﻦ B12 ﻭ ﺍﺳﻴﺪﻓﻮﻟﻴﮏ ﺍﻳﻦ ﺑﻴﻤﺎﺭﺍﻥ ﺑﺎ ﺍﺳﺘﻔﺎﺩﻩ ﺍﺯ ﮐﻴﺖ ﺁﺯﻣﺎﻳﺸﮕﺎﻫﻲ Siemens( ,)Healthineers Active-B12 (AB12) Atellica® IM Analyzer and ADVIA Centaur® CP ﺍﻧﺪﺍﺯﻩﮔﻴﺮﻱ ﮔﺮﺩﻳﺪ. ﻧﺘﺎﻳﺞ ﺣﺎﺻﻞ ﺍﺯ ﺍﻧﺪﺍﺯﻩﮔﻴﺮﻱﻫﺎ ﺑﺎ ﺍﺳﺘﻔﺎﺩﻩ ﺍﺯ ﻧﺮﻡﺍﻓﺰﺍﺭ 18.0 SPSS ﻭ ﺑﺎ ﺳﻄﺢ ﻣﻌﻨﻲﺩﺍﺭﻱ 0/05 ﺗﺤﻠﻴﻞ ﺁﻣﺎﺭﻱ ﮔﺮﺩﻳﺪ. ﻳﺎﻓﺘﻪﻫﺎ: 184 ﺑﻴﻤﺎﺭ )76 ﻣﺮﺩ ﻭ 108 ﺯﻥ( ﺑﺎ ﻣﻴﺎﻧﮕﻴﻦ ﺳﻨﻲ 9/49 ± 33/65 ﺳﺎﻝ ﻭﺍﺭﺩ ﻣﻄﺎﻟﻌﻪ ﺷﺪﻧﺪ. 52/8 ﺩﺭﺻﺪ ﺍﺯ ﺑﻴﻤﺎﺭﺍﻥ ﮔﺮﻭﻩ ﻣﻄﺎﻟﻌﻪ ﻭ 8 ﺩﺭﺻﺪ ﺍﺯ ﺑﻴﻤﺎﺭﺍﻥ ﮔﺮﻭﻩ ﮐﻨﺘﺮﻝ ﮐﻤﺒﻮﺩ ﻭﻳﺘﺎﻣﻴﻦ B12 ﺩﺍﺷﺘﻨﺪ ﮐﻪ ﺍﺯ ﺍﻳﻦ ﺣﻴﺚ ﺗﻔﺎﻭﺕ ﺑﻴﻦ ﺩﻭ ﮔﺮﻭﻩ ﻣﻌﻨﻲﺩﺍﺭ ﺑﻮﺩ )0.05 < p(. 28/5 ﺩﺭﺻﺪ ﺍﺯ ﺑﻴﻤﺎﺭﺍﻥ ﮔﺮﻭﻩ ﻣﺪﺍﺧﻠﻪ ﻭ 20 ﺩﺭﺻﺪ ﺍﺯ ﺑﻴﻤﺎﺭﺍﻥ ﮔﺮﻭﻩ ﮐﻨﺘﺮﻝ ﮐﻤﺒﻮﺩ ﺍﺳﻴﺪﻓﻮﻟﻴﮏ ﺩﺍﺷﺘﻨﺪ ﮐﻪ ﺗﻔﺎﻭﺕ ﺑﻴﻦ ﺩﻭ ﮔﺮﻭﻩ ﺍﺯ ﺍﻳﻦ ﺣﻴﺚ ﻣﻌﻨﻲﺩﺍﺭ ﻧﺒﻮﺩ )0.05 > p(. ﺑﺤﺚ ﻭ ﻧﺘﻴﺠﻪﮔﻴﺮﻱ: ﺑﺮ ﺍﺳﺎﺱ ﻧﺘﺎﻳﺞ ﺍﻳﻦ ﻣﻄﺎﻟﻌﻪ، ﮐﻤﺒﻮﺩ ﻭﻳﺘﺎﻣﻴﻦ B12 ﻣﻲﺗﻮﺍﻧﺪ ﺩﺭ ﺍﺑﺘﻼ ﺑﻪ ﺯﺧﻢﻫﺎﻱ ﺁﻓﺘﻲ ﺭﺍﺟﻌﻪ ﻧﻘﺶ ﺍﺳﺎﺳﻲ ﺭﺍ ﺍﻳﻔﺎ ﮐﻨﺪ. ﮐﻤﺒﻮﺩ ﺍﺳﻴﺪﻓﻮﻟﻴﮏ ﻧﻘﺸﻲ ﺩﺭ ﺑﺮﻭﺯ ﺯﺧﻢﻫﺎﻱ ﺁﻓﺘﻲ ﺭﺍﺟﻌﻪ ﻧﺪﺍﺭﺩ.

Background & Aims: Recurrent Aphthous Stomatitis (RAS) is one of the most common painful oral mucosal conditions seen among patients. This study aimed to compare the vitamin B12 and folate intake in RAS-positive patients with the control group. Materials & Methods: In this cross-sectional study, 184 patients who were referred to Taleghani Hospital (Urmia, Iran) participated in the study. Vitamin B12 and folate serum levels were measured using Vitamin B12 Assay Kit (Siemens Healthineers Active-B12 (AB12) assay offered on the Atellica® IM Analyzer and ADVIA Centaur® CP), then oral examination of patients were taken to rule out the prevalence of RAS between participants. The serum level of vitamin B12 and folate were compared between patients with RAS and control group. The data were analyzed by IBM SPSS 20.0 (Chicago, USA). Results: The study subjects had significantly lower daily intake of vitamin B12 (p < 0.0001) as compared to the controls. No significant differences were observed with regard to folate intake between two groups (p = 0.579). Conclusion: Our results demonstrated that patients with RAS are more likely to have lower dietary intakes of vitamin B12 than the control group, but no difference was observed between two groups concerning the folate intake. These findings suggest that consuming sufficient amounts of Vitamin B12 may be a useful strategy to reduce the number and/or duration of RAS episodes.